<DOC>
	<DOC>NCT01279473</DOC>
	<brief_summary>This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.</brief_summary>
	<brief_title>Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients who complete CAMN107A1101 and obtained Informed concent by document</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Philadelphia Chromosome Positive, ph+ ALL</keyword>
	<keyword>Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)</keyword>
</DOC>